公开(公告)号：US4720483A

公开(公告)日：1988-01-19

申请号：US819168

申请日：1986-01-15

申请人： Hendrik S. Jansz ,  Cornelis J. M. Lips ,  Paul H. Steenbergh ,  Hans Rink ,  Peter Sieber

发明人： Hendrik S. Jansz ,  Cornelis J. M. Lips ,  Paul H. Steenbergh ,  Hans Rink ,  Peter Sieber

IPC分类号： G01N33/50 ,  A61K35/74 ,  A61K38/00 ,  A61K38/22 ,  A61K38/23 ,  A61K39/395 ,  A61P1/00 ,  A61P3/00 ,  A61P9/04 ,  A61P9/08 ,  A61P9/12 ,  A61P25/00 ,  C07K1/113 ,  C07K7/00 ,  C07K14/00 ,  C07K14/575 ,  C07K14/585 ,  C12N1/00 ,  C12N15/00 ,  C12N15/09 ,  C12N15/16 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  A61K37/24 ,  C07K7/10

CPC分类号： C07K14/57527 ,  A61K38/00 ,  Y10S930/26

摘要： Described are peptides that have, as partial sequence of a larger peptide, or exclusively, the amino acid sequence of the formula I ##STR1## in which the cysteine residues can form intra- or inter-molecular disulphide bridges, and derivatives thereof having an amidated terminal carboxy group and/or an acylated terminal amino group, and their salts, DNA sequences that code for the mentioned peptides, micro-organisms that contain these DNA sequences, processes for the manufacture thereof, pharmaceutical preparations that contain the mentioned peptides in the form of their amides, and the use of these peptide-amides for the treatment of coronary circulation disorders and bone metabolism disorders.

摘要翻译： 描述的是具有作为较大肽的部分序列或仅排除式I的氨基酸序列的肽（I）ArgSerGlyGlyMetValLysSerAsnPheValProThrAsnValGlySer- + TR LysAlaPhe-的肽，其中半胱氨酸残基可以形成分子内或分子间 具有酰胺化末端羧基和/或酰化末端氨基的二硫键及其衍生物及其盐，编码所述肽的DNA序列，含有这些DNA序列的微生物，其制备方法，药物 含有上述酰胺形式的肽的制剂，以及这些肽 - 酰胺用于治疗冠状动脉循环障碍和骨代谢障碍的用途。